Background
==========

Pancreatic ductal adenocarcinoma (PDAC), the most common pancreatic neoplasm, is expected to turn into the second most common cause of deaths associated with cancer by 2030 \[[@b1-medscimonit-24-2368],[@b2-medscimonit-24-2368]\]. It is estimated that a total of 45,220 patients will be diagnosed with pancreatic cancer and 38,460 will die of this disease in the United States in 2013 \[[@b3-medscimonit-24-2368]\]. Risk factors for PDAC include age, gender, ethnicity, cigarette smoking \[[@b4-medscimonit-24-2368],[@b5-medscimonit-24-2368]\]. In addition, a very poor overall prognosis is one of the most important characteristic of PDAC, and the median survival time after diagnosis is only 3--5 months \[[@b6-medscimonit-24-2368]\]. Thus, accurate early diagnosis for PDAC is needed and discovery of the molecular mechanisms may provide a new option for the early diagnosis of PDAC.

Recently, a wealth of previous studies has been applied to gain a better understanding of the molecular mechanisms of PDAC. One study showed that *SEL1L* (*Sel-1-like*) was downregulated by upregulated has-miR-155 in PDAC patients, which suggested that specific miRNAs played important roles in the pathogenesis of this disease \[[@b7-medscimonit-24-2368]\]. Steele et al. suggested that microRNA (miRNA) such as miR-21 might serve as a screening tool for PDAC in the future \[[@b8-medscimonit-24-2368]\]. The miR-10b is upregulated in PDAC and can be used as a diagnostic marker in suspicious pancreatic lesions \[[@b9-medscimonit-24-2368]\]. Furthermore, the serum *MMP7* (matrix metalloproteinase 7) level in PDAC patients correlates with metastatic disease and survival \[[@b10-medscimonit-24-2368]\]. Oji et al. indicated that *WT1* (Wilms Tumor 1) played a significant part in the tumorigenesis of PDAC and provided a new option for the treatment of this disease \[[@b11-medscimonit-24-2368]\]. In addition, mutation of *TP53* (tumor protein 53) contributes to rapid progression of premalignant cells to pancreatic tumor and *FoxM1* (forkhead box M1) can be used as prognostic molecular marker for PDAC \[[@b12-medscimonit-24-2368],[@b13-medscimonit-24-2368]\]. Besides, activation of the Jak/Stat3 (Janus kinase/signal transducer and activator of transcription 3) pathway is related with adverse outcome of PDAC after resection \[[@b14-medscimonit-24-2368]\]. The Wnt pathway regulates the metastasis-promoting mucin 4 in PDAC, and then contributes to disease metastases and progression \[[@b15-medscimonit-24-2368]\]. However, since these genes and pathways are not sufficient to clarify the molecular mechanisms of the PDAC, there is a need to identify more pivotal genes and pathways important in the progression of this disease.

Gene expression technologies are increasingly being used to identify DEGs (differentially expressed genes) in neoplastic tissues compared with their normal tissues \[[@b16-medscimonit-24-2368]\]. In the present study, we downloaded the array data of GSE74629 and analyzed the DEGs associated with PDAC. Then, functional network analyses were performed for these DEGs. In addition, protein-protein interaction (PPI) network and important clustering modules were analyzed. We aimed to find pivotal genes and pathways involved in PDAC, and explore possible molecular markers for the early diagnosis of the disease.

Material and Methods
====================

Microarray data
---------------

The array data of GSE74629 was downloaded from GEO (Gene Expression Omnibus, *<http://www.ncbi.nlm.nih.gov/geo/>*) database with the platform of GPL10558 (Illumina HumanHT-12 V4.0 expression beadchip, Jaen, Spain). A total of 34 PDAC samples and 16 healthy samples were included in this study.

Data preprocessing
------------------

The downloaded non-normalized gene expression data were preprocessed by limma (linear models for microarray) \[[@b17-medscimonit-24-2368]\] in R package, including background correcting, normalizing and calculating expression. Then, the probe ID was transformed to gene symbol with illuminaHumanv4.db \[[@b18-medscimonit-24-2368]\] in R annotation package and the probe that was not matched with gene symbol was eliminated. For one gene symbol mapped by several probes, the mean value of these probes was set as the final gene expression level. Finally, totally 21,318 gene expression values were obtained.

Screening of DEGs
-----------------

The DEGs in PDAC samples compared with healthy samples were analyzed with limma. The *p*-values were calculated by *t*-test \[[@b19-medscimonit-24-2368]\] in limma package. BH (Benjamini-Hochberg) \[[@b20-medscimonit-24-2368]\] was used to adjust *p*-values into FDR (false discovery rate) values. FDR \<0.05 and \|log2FC (fold change)\| ≥0.58 were set as cutoff criterion for DEGs.

Functional network analysis
---------------------------

The ReactomeFIViz app \[[@b21-medscimonit-24-2368]\] can calculate correlations (as weights for edges in the whole functional interaction network) among genes involved in the same functional interactions, apply Monte Carlo localization graph clustering algorithm to the weighted functional interaction network, and form a sub-network for selected network modules on the basis of module size and average correlation.

In the present study, Cytoscape \[[@b22-medscimonit-24-2368]\] and ReactomeFIViz app were used to analyze gene functional interaction network. Modules size ≥6 and average correlation ≥0.25 were set as criteria. Subsequently, pathway enrichment analyses were performed for each function module, and biological pathways involved by each module gene were observed with FDR \<0.05.

PPI network analysis
--------------------

STRING (Search Tool for the Retrieval of Interacting Genes) \[[@b23-medscimonit-24-2368]\] is a database used to provide information of interaction of proteins, and neighborhood, gene fusion, co-occurrence, co-expression experiments, databases and text mining were prediction method of this database. In this study, the input gene sets were gene modules and species were Homo sapiens. PPI score \>0.9 was set as the cutoff value and at least one protein interaction nodes was a module gene. PPI networks were constructed with Cytoscape software.

PPI network clustering modules analyses
---------------------------------------

KEGG (Kyoto Encyclopedia of Genes and Genomes) can be used to reveal functions of genes or other molecules \[[@b24-medscimonit-24-2368]\]. The subnetwork modules in the PPI network tended to take part in common biological processes. ClusterONE \[[@b25-medscimonit-24-2368]\] was used to analyze network modules, and the KEGG pathway enrichment analyses for modules were performed. Modules that *p*-value \<3E-4 were set as significant modules.

Results
=======

Data processing and DEGs analysis
---------------------------------

As shown in [Figure 1](#f1-medscimonit-24-2368){ref-type="fig"}, a total of 630 upregulated and 1,002 downregulated genes were differently expressed in PDAC samples compared with healthy samples.

Functional network analysis
---------------------------

A total of 13 subnetwork modules including 146 nodes and 684 gene pairs were included in the network ([Figure 2](#f2-medscimonit-24-2368){ref-type="fig"}). Particularly, the average correlation of module 0, module 3, and module 8 was greater than 0.6, which indicated strong correlation ([Table 1](#t1-medscimonit-24-2368){ref-type="table"}).

Ribosomal protein genes, such as *RPL13* (ribosomal protein L13)*, RPL17* (ribosomal protein L17)*, RPL21* (ribosomal protein L21)*, RPL22* (ribosomal protein L22)*, RPL23* (ribosomal protein L23)*, RPL26* (ribosomal protein L26)*, RPL31* (ribosomal protein L31)*, RPL35A* (ribosomal protein L35A)*, RPL36A* (ribosomal protein L36A)*, RPL37* (ribosomal protein L37)*, RPL39* (ribosomal protein L39)*, RPL7* (ribosomal protein L7)*, RPS17* (ribosomal protein S17),*RPS23* (ribosomal protein S23)*, RPS3A* (ribosomal protein S3A)*, RPS6* (ribosomal protein S6) and*RPS7* (ribosomal protein S7) were enriched in module 0. *NUP107* (nucleoporin 107 kDa) and *NUP160* (nucleoporin 160 kDa) were enriched in module 3. *HNRNPU* (heterogeneous nuclear ribonucleoprotein U) was enriched in module 8.

Pathway analysis of functional network module and PPI network analysis
----------------------------------------------------------------------

Pathways significantly enriched by each module are shown in [Table 2](#t2-medscimonit-24-2368){ref-type="table"}. Ribosomal protein genes were mainly enriched in three pathways including SRP-dependent co-translational protein targeting to membrane, eukaryotic translation termination, and ribosome. *NUP107* and *NUP160* were mainly enriched in two pathways including hexose transport and metabolism of non-coding RNA. *HNRNPU* was mainly enriched in the spliceosome pathway.

The PPI network for other DEGs interacted with 13 module genes was shown in [Figure 3](#f3-medscimonit-24-2368){ref-type="fig"}. A total of 243 nodes and 676 interaction pairs were included in this network.

PPI network clustering modules analyses
---------------------------------------

We obtained two subnetwork modules with ClusterOne ([Figure 4](#f4-medscimonit-24-2368){ref-type="fig"}), and the GO (Gene Ontology) and KEGG pathways significantly enriched in two subnetwork modules are shown in [Figure 5](#f5-medscimonit-24-2368){ref-type="fig"}.

Cluster 1 was enriched by most of the ribosomal protein genes, and cluster 2 was enriched by *NUP160* and *HNRNPU*. The ribosome pathway and the spliceosome pathway were significantly enriched in cluster 1 and cluster 2, respectively.

In this study, modules and clusters had similar meanings. The "modules" were obtained using ReactomeFI, and the "clusters" were obtained by ClusterOne. Sometimes, the results obtained by ClusterOne also could be called "modules". The main difference between modules and clusters was that the former was function modules and the latter was cluster modules. In the present study, the results obtained by ClusterOne were presented as "clusters".

Discussion
----------

With the gene expression patterns obtained from the GEO database, a total of 630 upregulated and 1,002 downregulated genes were differently expressed in PDAC samples compared with healthy samples in our present study. Our results showed some ribosomal protein genes with higher average correlation in module 0 were enriched in the ribosome pathway. *NUP107* and *NUP160* were enriched in module 3. *HNRNPU,* with higher average correlation in module 8, was enriched in the spliceosome pathway. The ribosome pathway and the spliceosome pathway were significantly enriched in cluster 1 and cluster 2, respectively.

*RPS6* is an mTOR effector and the mTOR pathway is activated in PDAC \[[@b26-medscimonit-24-2368],[@b27-medscimonit-24-2368]\]. Phosphorylation of *RPS6* attenuates DNA damage and tumor suppression for pancreatic cancer progression \[[@b26-medscimonit-24-2368]\]. *RPS26* regulates *p53* activity and *p53* plays an important role in the development of PDAC \[[@b28-medscimonit-24-2368],[@b29-medscimonit-24-2368]\]. Furthermore, the abundance of *RPS8* can determine the susceptibility of pancreatic cancer cells to gemcitabine treatment \[[@b30-medscimonit-24-2368]\]. In addition, a higher abundance of *RPS8* is related to worse survival of PDAC, and *RPS8* may be an important prognostic factor \[[@b31-medscimonit-24-2368]\]. In addition, downregulation of *RPL15* is related to tumor development in PDAC \[[@b32-medscimonit-24-2368]\]. Thus, some ribosomal protein genes, such as *RPS6*, *RPS26* and*RPS8*, have been associated with the progression of PDAC. In the present study, some ribosomal protein genes with higher average correlation in module 0 were also enriched in cluster 1. Although the significant roles of some other ribosomal protein genes have not been fully discussed, we speculated that ribosomal protein genes may be involved in the development of PDAC.

*Nup170* and *Nup160* are significant components of the Nup107--160 complex, and the Nup107--160 complex plays an important role in the regulation of NPC (nuclear pore complex) assembly \[[@b33-medscimonit-24-2368]\]. On the one hand, the Nup107--160 complex regulates microtubule polymerization at kinetochores \[[@b34-medscimonit-24-2368]\]. Nup107--160 complex is an essential component for the recruitment of RanGAP1 (Ran GTPase-activating protein 1), RanBP2 (Ran GTPase-activating protein 2), and Crm1 (chromosomal maintenance 1) to these structures at kinetochores \[[@b35-medscimonit-24-2368]\]. Furthermore, *Nup170* is involved in kinetochore function and the overexpression of kinetochore may contribute to the development of tumor via driving chromosome instability \[[@b36-medscimonit-24-2368],[@b37-medscimonit-24-2368]\]. On the other hand, Ran is an essential protein in the formation of nuclear envelope, and this mechanism is dependent on importin-β associated with Nup107--Nup160 \[[@b38-medscimonit-24-2368]\]. Furthermore, Ran plays a significant role in the metastatic progression of cancer \[[@b38-medscimonit-24-2368]\]. One study indicated that *Nup170* was upregulated in pancreatic cancer \[[@b33-medscimonit-24-2368]\]. In our present study, *NUP107* and *NUP160* were enriched in module 3, and *NUP160* also was enriched in cluster 2. Thus, we speculated that *Nup170* and *Nup160* may play important roles in the development of PDAC.

*HNRNPU* can modulate *WT1* transcriptional activation by directly interacting with *WT1* \[[@b39-medscimonit-24-2368]\], and *WT1* plays a significant part in the tumorigenesis of PDAC \[[@b11-medscimonit-24-2368]\]. *HNRNPU* interacts with *MDM2* (E3 ubiquitin-protein ligase Mdm2) involving the degradation of *p53* \[[@b40-medscimonit-24-2368]\]. Furthermore, *p53* as tumor suppressor genes plays a part in cell cycle regulation, and mutation of this gene may promote the growth of tumor cell \[[@b41-medscimonit-24-2368]\]. Thus, *HNRNPU* may play a role in PDAC progression indirectly. In this study, *HNRNPU* with higher average correlation in module 8 was enriched in cluster 2. Therefore, our results were similar to other research and suggest that *HNRNPU* may be an important gene involved in the development of PDAC.

One study indicated that *Myc* might be involved in the early neoplastic progression of PDAC \[[@b42-medscimonit-24-2368]\]. Furthermore, the spliceosome is a treatment entry point for *Myc*-driven cancer \[[@b43-medscimonit-24-2368]\]. Thus, spliceosome may play important roles in the PDAC progression. In this study, the spliceosome pathway was significantly enriched in cluster 2, and *HNRNPU* was enriched in the spliceosome pathway. Therefore, *HNRNPU* may play important roles in the development of PDAC via the spliceosome pathway. In addition, the ribosome pathway was significantly enriched in cluster 1, and the ribosomal protein genes mainly enriched in the ribosome pathway. In addition, as aforementioned, the ribosomal protein genes may be involved in the development of PDAC. Therefore, ribosomal protein genes may play significant parts in the development of PDAC via ribosome pathway.

Conclusions
===========

Ribosomal protein genes, *Nup170*, *Nup160*,*HNRNPU*, and the ribosome pathway, as well as the spliceosome pathway, may play important roles in PDAC progression. In addition, ribosomal protein genes, *Nup170*, *Nup160,* and*HNRNPU* may be used as possible molecular markers for the early diagnosis of the disease. A limitation of this study is a lack of experimental verification, thus, further research is needed about genes that are used for early diagnosis of the disease and other possible molecular markers of PDAC.
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###### 

Information list of 13 sub network modules.

  Module   Nodes in module   Node percentage   Average correlation   Node list
  -------- ----------------- ----------------- --------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  0        25                0.1701            0.6255                CAND1, EEF1B2, EIF3E, RPL13, RPL17, RPL21, RPL22, RPL23, RPL26, RPL31, RPL35A, RPL36A, RPL37, RPL39, RPL7, RPS17, RPS23, RPS3A, RPS6, RPS7, SEC11C, SEC61G, SRP9, SRPRB, UPF3A
  1        18                0.1224            0.4769                ZFP3, ZFP82, ZNF10, ZNF146, ZNF195, ZNF260, ZNF266, ZNF286B, ZNF30, ZNF302, ZNF329, ZNF483, ZNF514, ZNF529, ZNF544, ZNF696, ZNF789, ZNF91
  2        15                0.102             0.4808                ICT1, MRPL1, MRPL12, MRPL24, MRPL3, MRPL38, MRPL39, MRPL48, MRPL50, MRPS17, MRPS23, MRPS26, MRPS30, MRPS33, MRPS35
  3        11                0.0748            0.602                 CENPT, GSR, KNTC1, KPNA3, MIS12, NUP107, NUP160, NUP205, NUP54, NUP88, PSIP1
  4        11                0.0748            0.4621                AKR1C3, CA4, CARS, EIF2B3, FAIM3, MYC, PAICS, PRMT6, SUB1, TFB2M, TNS3
  5        11                0.0748            0.4021                BAZ2A, DDAH2, DNMT1, EID2, FKBP3, HDAC2, PADI4, SAP30, TAF6, TBC1D8, WDTC1
  6        9                 0.0612            0.5257                CD40LG, DUSP12, DUSP14, DUSP3, EIF2AK3, KMT2C, MAP3K4, MAPK14, MAPKAPK5
  7        9                 0.0612            0.4102                ACTA2, ITGA2B, ITGB5, MYBPC3, MYL9, SORBS3, TLN1, TPM1, TPM2
  8        8                 0.0544            0.6486                CPSF2, HNRNPA0, HNRNPH1, HNRNPU, SNRPA1, SRSF2, SRSF7, ZRANB2
  9        8                 0.0544            0.5985                AKR1B1, CFLAR, CTDSPL, DROSHA, SMAD3, TFE3, TGIF2, ZMYND11
  10       8                 0.0544            0.4305                AK3, CDK5RAP2, CEP78, OFD1, TUBA4A, TUBB4B, TUBGCP5, VBP1
  11       7                 0.0476            0.4346                CARD16, DNAJC10, ERLEC1, HSPE1, SLX4, USP10, VCP
  12       7                 0.0476            0.3656                FES, FGF9, GSN, PELP1, PIK3R1, PIK3R5, PXK

###### 

Pathways significantly enriched by each module.

  Module   GeneSet                                                          FDR           Nodes
  -------- ---------------------------------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  0        SRP-dependent cotranslational protein targeting to membrane(R)   \<1.667e-04   RPL17, RPL36A, RPL13, RPL37, RPL39, RPL7, RPS3A, RPL31, RPS23, RPL35A, SEC11C, RPL26, SRPRB, RPS6, RPS7, RPL23, RPS17, RPL22, RPL21, SEC61G, SRP9
  0        Eukaryotic Translation Termination(R)                            \<1.667e-04   RPL17, RPL36A, RPL13, RPL37, RPL39, RPL7, RPS3A, RPL31, RPS23, RPL35A, RPL26, RPS6, RPS7, RPL23, RPS17, RPL22, RPL21
  0        Ribosome(K)                                                      \<1.667e-04   RPL17, RPL36A, RPL13, RPL37, RPL39, RPL7, RPS3A, RPL31, RPS23, RPL35A, RPL26, RPS6, RPS7, RPL23, RPS17, RPL22, RPL21
  2        Mitochondrial translation(R)                                     \<1.000e-03   MRPS35, MRPS17, MRPS26, MRPL1, MRPS33, MRPL50, MRPL3, MRPS23, MRPS30, MRPL24, MRPL12, ICT1, MRPL38, MRPL39, MRPL48
  2        Ribosome(K)                                                      \<5.000e-04   MRPS17, MRPL1, MRPL3, MRPL24, MRPL12
  3        ISG15 antiviral mechanism(R)                                     \<1.000e-03   NUP160, NUP88, NUP205, NUP107, NUP54, KPNA3
  3        Hexose transport(R)                                              \<5.000e-04   NUP160, NUP88, NUP205, NUP107, NUP54
  3        Metabolism of non-coding RNA(R)                                  \<3.333e-04   NUP160, NUP88, NUP205, NUP107, NUP54
  5        NoRC negatively regulates rRNA expression(R)                     \<1.000e-03   SAP30, HDAC2, DNMT1, BAZ2A
  5        Signaling events mediated by HDAC Class I(N)                     \<5.000e-04   SAP30, HDAC2, FKBP3
  5        Hedgehog signaling events mediated by Gli proteins(N)            3.83e-02      SAP30, HDAC2
  6        Oxidative stress response(P)                                     \<1.000e-03   DUSP3, MAP3K4, DUSP14, MAPK14, MAPKAPK5, DUSP12
  6        MAPK signaling pathway(K)                                        8.00e-03      DUSP3, MAP3K4, MAPK14, MAPKAPK5
  6        p38 MAPK signaling pathway(N)                                    2.17e-02      MAP3K4, MAPK14
  7        Muscle contraction(R)                                            \<1.000e-03   SORBS3, TLN1, ACTA2, MYBPC3, ITGB5, TPM2, TPM1, MYL9
  7        Hypertrophic cardiomyopathy (HCM)(K)                             \<5.000e-04   MYBPC3, ITGB5, TPM2, TPM1, ITGA2B
  7        Dilated cardiomyopathy(K)                                        \<3.333e-04   MYBPC3, ITGB5, TPM2, TPM1, ITGA2B
  8        Processing of Capped Intron-Containing Pre-mRNA(R)               \<1.000e-03   SRSF2, SNRPA1, SRSF7, HNRNPH1, CPSF2, HNRNPA0, HNRNPU
  8        Spliceosome(K)                                                   \<5.000e-04   SRSF2, SNRPA1, SRSF7, HNRNPU
  8        spliceosomal assembly(B)                                         1.33e-03      SRSF2, SNRPA1
  9        Regulation of nuclear SMAD2/3 signaling(N)                       \<1.000e-03   TFE3, SMAD3, TGIF2
  9        Regulation of cytoplasmic and nuclear SMAD2/3 signaling(N)       7.00e-03      CTDSPL, SMAD3
  10       Mitotic G2-G2/M phases(R)                                        \<1.000e-03   OFD1, TUBGCP5, CEP78, TUBA4A, CDK5RAP2, TUBB4B
  10       Assembly of the primary cilium(R)                                \<5.000e-04   OFD1, CEP78, TUBA4A, CDK5RAP2, TUBB4B
  10       Protein folding(R)                                               \<3.333e-04   VBP1, TUBA4A, TUBB4B
  11       Protein processing in endoplasmic reticulum(K)                   2.00e-03      VCP, DNAJC10, ERLEC1
  11       Hedgehog ligand biogenesis(R)                                    2.15e-02      VCP, ERLEC1
  12       Signaling by SCF-KIT(R)                                          7.00e-03      FGF9, FES, PIK3R1
  12       Nongenotropic Androgen signaling(N)                              9.00e-03      PELP1, PIK3R1
  12       Osteopontin-mediated events(N)                                   7.67e-03      GSN, PIK3R1

FDR -- false discovery rate.
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